Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization. - Test2 - elhamkhani - TriplyDB

Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization.

Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization.

http://www.wikidata.org/entity/Q34746665

about

Lorcaserin: drug profile and illustrative model of the regulatory challenges of weight-loss drug development The use of lorcaserin in the management of obesity: a critical appraisal Head-twitch response in rodents induced by the hallucinogen 2,5-dimethoxy-4-iodoamphetamine: a comprehensive history, a re-evaluation of mechanisms, and its utility as a model.Lorcaserin, a 5-HT(2C) receptor agonist, reduces body weight by decreasing energy intake without influencing energy expenditure Pharmacological targeting of the serotonergic system for the treatment of obesity The GLP-1 agonist, liraglutide, as a pharmacotherapy for obesity The stomach in health and disease Neural control of energy balance: translating circuits to therapies Serotonin 5-HT2 receptor interactions with dopamine function: implications for therapeutics in cocaine use disorder Parallel functional activity profiling reveals valvulopathogens are potent 5-hydroxytryptamine(2B) receptor agonists: implications for drug safety assessment Enteropeptidase: a gene associated with a starvation human phenotype and a novel target for obesity treatment New and emerging drug molecules against obesity.Structure and function of serotonin G protein-coupled receptors.The pharmacological treatment and management of obesity.Pharmacotherapy of Obesity: Clinical Trials to Clinical Practice.PSD-95 is essential for hallucinogen and atypical antipsychotic drug actions at serotonin receptors The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors Bariatric endocrinology: principles of medical practice.Safety of antiobesity drugs.Managing overweight and obesity in adults to reduce cardiovascular disease risk.Recent advances in clinical practice challenges and opportunities in the management of obesity.Behavioral and pharmacologic therapies for obesity.Present and future: pharmacologic treatment of obesity Lorcaserin and adiposopathy: 5-HT2c agonism as a treatment for 'sick fat' and metabolic disease.The use of serotonergic drugs to treat obesity--is there any hope?Selective serotonin 5-HT(2C) receptor activation suppresses the reinforcing efficacy of cocaine and sucrose but differentially affects the incentive-salience value of cocaine- vs. sucrose-associated cues.Characterization of the 5-HT2C receptor agonist lorcaserin on efficacy and safety measures in a rat model of diet-induced obesity.Current pharmacotherapy for obesity: extrapolation of clinical trials data to practice.Novel 4-substituted-N,N-dimethyltetrahydronaphthalen-2-amines: synthesis, affinity, and in silico docking studies at serotonin 5-HT2-type and histamine H1 G protein-coupled receptors.Lorcaserin, a 5-HT2C agonist, decreases nicotine self-administration in female rats.Drug discovery targeting human 5-HT(2C) receptors: residues S3.36 and Y7.43 impact ligand-binding pocket structure via hydrogen bond formation The utility of animal models to evaluate novel anti-obesity agents.Integrated Approaches for Genome-wide Interrogation of the Druggable Non-olfactory G Protein-coupled Receptor Superfamily.We Need 2C but Not 2B: Developing Serotonin 2C (5-HT2C) Receptor Agonists for the Treatment of CNS Disorders.The 5-HT2C receptor agonist lorcaserin reduces nicotine self-administration, discrimination, and reinstatement: relationship to feeding behavior and impulse control Individual differences in the improvement of cocaine-induced place preference response by the 5-HT2C receptor antagonist SB242084 in rats Weight Loss After RYGB Is Independent of and Complementary to Serotonin 2C Receptor Signaling in Male Mice.Role for serotonin2A (5-HT2A) and 2C (5-HT2C) receptors in experimental absence seizures.ACS chemical neuroscience molecule spotlight on Lorcaserin.Clemizole and modulators of serotonin signalling suppress seizures in Dravet syndrome.

P2860

Q22241480-9ACF3E4E-A9A3-42F7-8856-110C8ECF2EE2 Q24594774-BBE13C08-1A99-459C-ABDC-1C33F411A06A Q24595389-CB209E48-9A82-472B-A73D-90F9EAA97B1E Q24611940-81BE60DB-3F20-439D-AD0A-468CBCB73368 Q24658013-6069F5C3-E92D-4D1F-90D4-CD87359593FB Q26765609-15CFFB53-33D7-4F25-A046-5564B4D9F7B8 Q26784036-727E61B1-A8FD-4619-89C4-E7B9C9EFEE18 Q27005992-E005630A-D334-4A7F-9B9E-FB0F9D87BC57 Q27015917-1E71083B-F221-42A9-9F9F-CCAF3BF01A21 Q28250560-D03DEF6B-DABD-4F25-8DC6-114722B76CAF Q28485316-1BE5D774-3B92-45FC-8C1C-BC868CF076AD Q30353872-092CD23E-EE41-4B98-9100-568E41C5869E Q30382524-DC6A12A5-8A17-4FD0-BF9F-1B5C8791A45F Q30399340-3C5FBEA1-957B-490B-90CD-984C61ED3C30 Q30400748-30614B21-9C60-4771-8947-F0EAC8613720 Q30482703-49D707A7-353F-4020-9477-551C1C75F30D Q30486707-91EFA61F-B3C7-42BD-8E07-8F5DC0371ABF Q33677790-467AC787-8B6C-4824-A718-6515221A1654 Q34016243-9BF7E0C5-D5A2-4F2F-9D27-6F25385EAC90 Q34106367-960775FE-3073-4EFF-8810-26D3EB2CC3CD Q34219768-4E248BE4-CD41-4DE7-BC82-2F414783F17C Q34543656-AA38C602-710C-452F-AA8D-32B3EC34A888 Q34572487-3518848A-BC30-4E1F-AD28-034FB0DEC160 Q34659424-32BC65CC-563A-4DA3-8A63-116189ED48A2 Q34712327-066A827D-1683-4404-A6B7-3246A40832B3 Q35046675-7E58F78F-4B0D-42A4-961F-D3997B16A589 Q35049574-F371D4C3-A8CC-43BD-88DA-D67580248822 Q35096627-E5E41A33-2CAD-4B66-B1FB-55C12CDC8766 Q35186684-6A7DCA50-86AC-4A98-8163-5DD8B54FE2F2 Q35188133-72E5808B-FF1E-48C1-A95D-E0A229318D29 Q35573424-F3E29053-E03E-471E-8910-F79BEC5E25C5 Q35589958-DD3390D3-7E36-4D26-A721-E15FE540F981 Q35671396-A422D8C4-8115-4C1B-A125-83FBD061863B Q35823591-B8DC662D-B0D6-44FE-A92D-A926C54F3F51 Q35837700-AFF4F416-9B47-4CC9-A169-75972A171E8D Q35856962-BB41FC5D-C477-48F8-A000-3C3FE6BC34CD Q35970910-BFF349AD-5AFD-4FAD-B807-3477B1AD6C1B Q35991747-032EEC66-EAC6-4D7C-9A5D-628F93A933AD Q36012315-4E9DD67C-799B-4876-A2F8-C75E915FEBF8 Q36245909-E125C89B-7170-43A7-91CB-ED51D9E0BBDC

P2860

Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization.

http://www.wikidata.org/entity/Q34746665

description

2008 nî lūn-bûn

@nan

2008 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Lorcaserin, a novel selective ...... rmacological characterization.

@ast

Lorcaserin, a novel selective ...... rmacological characterization.

@en

Lorcaserin, a novel selective ...... rmacological characterization.

@nl

type

label

Lorcaserin, a novel selective ...... rmacological characterization.

@ast

Lorcaserin, a novel selective ...... rmacological characterization.

@en

Lorcaserin, a novel selective ...... rmacological characterization.

@nl

prefLabel

Lorcaserin, a novel selective ...... rmacological characterization.

@ast

Lorcaserin, a novel selective ...... rmacological characterization.

@en

Lorcaserin, a novel selective ...... rmacological characterization.

@nl

P1433

Q34746665-83C98204-A91E-4D9C-A728-01C7E96A0C98

P1476

Q34746665-50B62069-AAC9-431B-B2FF-5A8A05823FE5

P2093

Q34746665-18929903-CF0E-4CD8-8776-CE207E3F7741

Q34746665-282AC102-F3B4-4F34-9EB0-3CEA53271A70

Q34746665-2B068414-1B30-4A7B-B1A9-8E3D2FA46A33

Q34746665-4E790580-8B8F-4B97-8099-D3F6DE33F573

Q34746665-60153836-0733-438D-AF41-25F4BDB9CE54

Q34746665-658AC8E4-A1BA-48D7-A052-C77B750E01CB

Q34746665-804625CB-CCBD-43E1-99D7-A1C46B655FF1

Q34746665-8BA1936A-0449-4219-BD4E-38625053BBBA

Q34746665-A1225F15-2C05-4484-9908-0668C0386011

Q34746665-A4EE4758-D348-4DB5-B69B-BE4AB55E7990

P304

Q34746665-2AB3D715-7D95-4552-8181-D79504B03455

P31

Q34746665-89EE5D1C-643B-451C-A638-E7E63C18AD3E

P356

Q34746665-85942D0C-7323-4035-B5E9-6241A5348AF7

P407

Q34746665-66AD613C-9D51-46DE-8214-FA0DE18E9801

P433

Q34746665-A5FF547F-A85A-44C2-AD56-B89B999A1612

P478

Q34746665-918FF8FD-BECC-46C9-A409-00F7B9F6A1D3

P577

Q34746665-29364690-B5C8-426B-88A9-08B7CEFA943F

P698

Q34746665-B0E0CF64-6CBB-4E08-A60B-FC18DB874D28

P921

Q34746665-0319D0B0-4218-47A7-A275-CBB68DB08B70

Q34746665-F1DE5514-9EF9-4837-A213-19699FC017D9

P356

JPET.107.133348

P1433

Journal of Pharmacology and Experimental Therapeutics

P1476

Lorcaserin, a novel selective ...... rmacological characterization.

@en

P2093

Andrew J Grottick

http://www.w3.org/2001/XMLSchema#string

Brian Smith

http://www.w3.org/2001/XMLSchema#string

Derek Chalmers

http://www.w3.org/2001/XMLSchema#string

Diane Yuskin

http://www.w3.org/2001/XMLSchema#string

Dominic Behan

http://www.w3.org/2001/XMLSchema#string

Frederique Menzaghi

http://www.w3.org/2001/XMLSchema#string

Hazel Reyes-Saldana

http://www.w3.org/2001/XMLSchema#string

Hussien Al-Shamma

http://www.w3.org/2001/XMLSchema#string

Kevin Whelan

http://www.w3.org/2001/XMLSchema#string

Michael Martin

http://www.w3.org/2001/XMLSchema#string

P304

577-587

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1124/JPET.107.133348

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

325

http://www.w3.org/2001/XMLSchema#string

P577

2008-02-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18252809

http://www.w3.org/2001/XMLSchema#string

P921

lorcaserin hydrochloride hemihydrate